MP
EBACW

Mangrove Partners’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Mangrove Partners’s Portfolio EBACW Stock Details EBACW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-187,740
Closed -$1.84M – 555
2022
Q2 		$1.84M Buy
+187,740
New +$31.8K 0.09% 337

Other funds holding EBACW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Mangrove Partners's EBACW Position: Q3 2022 in Review

Mangrove Partners sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q3 2022, closing a stake of 187,740 shares — an estimated $1.84M sold.

Mangrove Partners first reported a position in EBACW in Q2 2022 and held it in 1 quarter. The position peaked at $1.84M in Q2 2022. 29 funds tracked by Wall St. Rank hold EBACW as of Q3 2022.

  • Mangrove Partners reported no remaining European Biotech Acquisition Corp. Warrant position as of Q3 2022 after selling out during the quarter.
  • Mangrove Partners sold 187,740 European Biotech Acquisition Corp. Warrant shares in Q3 2022, an estimated $1.84M.
  • Mangrove Partners first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2022 and held it in 1 quarter.
  • Mangrove Partners's European Biotech Acquisition Corp. Warrant position peaked at $1.84M in Q2 2022.
  • 29 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q3 2022.

Based on Mangrove Partners's 13F filing for Q3 2022, filed 14 Nov 2022.